`
`ii)·
`LLJCEN T~S'
`P,b. N !Bi ZU !\-1/\8
`Business Use Only
`
`Lucentis PFS (RFB002)
`
`TRD SubTeam meeting
`
`Meeting Date: April 2, 2012
`Meeting Notes Date: April 5, 2012
`Author: ··••■ and team
`Room: WSJ-340.3.09
`Dial-in:
`
`Team Members : (✓ = Present,*= part-time)
`
`Team Members : (✓ = Present,*= part-time)
`
`Executive summary
`
`Lucentis CMC Sub Team Meeting Minutes, Meeting Date: April 2, 2012
`
`1 of 5
`
`CONTAINS CONFIDENTIAL BUSINESS INFORMATION, SUBJECT TO PROTECTIVE ORDER
`Novartis Exhibit 2075.001
`Regeneron v. Novartis, IPR2021 -00816
`
`
`
`Topics/ Notes
`
`I
`I►
`
`I·
`I►
`I►
`I
`
`Lucentis CMC Sub Team Meeting Minutes, Meeting Date: April 2, 2012
`
`2of 5
`
`CONTAINS CONFIDENTIAL BUSINESS INFORMATION, SUBJECT TO PROTECTIVE ORDER
`Novartis Exhibit 2075.002
`Regeneron v. Novartis, IPR2021 -00816
`
`
`
`-
`
`I
`
`11111111
`
`I
`I
`
`Lucentis CMC Sub Team Meeting Minutes, Meeting Date: April 2, 2012
`
`3of 5
`
`CONTAINS CONFIDENTIAL BUSINESS INFORMATION, SUBJECT TO PROTECTIVE ORDER
`Novartis Exhibit 2075.003
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`Action:
`
`I
`
`Lucentis CMC Sub Team Meeting Minutes, Meeting Date: April 2, 2012
`
`4 of 5
`
`CONTAINS CONFIDENTIAL BUSINESS INFORMATION, SUBJECT TO PROTECTIVE ORDER
`Novartis Exhibit 2075.004
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`WhO
`
`When
`
`- ----.
`
`. -
`
`Code
`
`-
`
`LF
`
`Action Plan
`
`What
`
`Lucentis CMC Sub Team Meeting Minutes, Meeting Date: April 2, 2012
`
`5of 5
`
`CONTAINS CONFIDENTIAL BUSINESS INFORMATION, SUBJECT TO PROTECTIVE ORDER
`Novartis Exhibit 2075.005
`Regeneron v. Novartis, IPR2021-00816
`
`